Rose Hill Apothecary Completes First Research-Grade Psilocybin Export to Brazil

LOS ANGELES- Rose Hill Apothecary, the research-grade psilocybin arm of Rose Hill Life Sciences, has executed its inaugural international export deal, shipping 18 kilograms of dried psilocybin-containing mushrooms to Biocase Brasil Importação e Comércio de Medicamentos Ltda. The export took place under Brazil’s regulatory framework to support medicinal research initiatives.

The shipment marks a significant milestone for Rose Hill, widely recognized as Jamaica’s largest legal producer of natural psilocybin and among the first to formally export the compound for scientific purposes. Brazilian authorities overseeing the import have greenlit the material exclusively for medicinal and scientific use, though specifics about the recipient research programs remain undisclosed.

In a statement, Rose Hill positioning the deal as a foundational step in building global research partnerships. The company emphasized its role in advancing “rigorous, science-based investigations into psilocybin’s therapeutic potential.” This move follows recent licensing agreements by Rose Hill with leading research institutions—underscoring a broader corporate strategy to deepen credibility and capability in psychedelic therapeutics .

The deal reflects rising international interest in psilocybin for clinical applications. Brazil, like other countries, is expanding frameworks that allow for therapeutic research using psychedelic compounds. Accessing research-grade psilocybin through compliant channels is vital as regulatory landscapes evolve.

The export’s timing aligns with Rose Hill’s previous announcements, including partnerships such as its recent licensing deal with Johns Hopkins University to study psilocybin’s role in neurological recovery—highlighting a coordinated, multi-front effort to support academic research with pharmaceutical-grade material .

As the first major export of this nature, the shipment to Brazil demonstrates increased market and scientific demand for psilocybin and signals Rose Hill’s intent to be a leading supplier in global clinical trials. Further details may emerge as Brazilian researchers publish findings or regulatory documents are released pertaining to the imported material.